Changes in dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) levels in human cerebrospinal fluid after L-dopa and deprenyl administration

Abstract

The dopamine (DA) and DOPAC levels were measured in cerebrospinal fluid (CSF) using a radioenzymatic method. The influence of a specific monoamine oxidase B inhibitor (deprenyl) on changes in DA and DOPAC levels was studied in untreated patients or after L-dopa administration. A single dose of deprenyl alone did not change the CSF DA and DOPAC levels, a three days' treatment, however, decreased both the DOPAC and DA concentrations. The acute administration of L-dopa caused an increase in CSF DA and DOPAC levels. The changes were smaller following repeated treatment. Deprenyl diminished the increase in DOPAC level after repeated L-dopa administration.